Erythema multiforme after Covishield/
            <scp>ChAdOx1</scp>
            vaccination

Subramani, Dharshini; Asnani, Divya Rajesh; Raman, Asharbh; Deora, Mahendra Singh; Gupta, Aayush

doi:10.1111/dth.15289

Cited by 4 publications

(3 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Table 1 [ 8 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 ] and Table 2 [ 39 40 41 42 43 44 ] presents the results obtained from evaluation of 31 eligible articles retrieved from the databases.…”

Section: Resultsmentioning

confidence: 99%

Occurrence of erythema multiforme following COVID-19 vaccination: a review

Yousefian

Khadivi

2023

Clin Exp Vaccine Res

View full text Add to dashboard Cite

The fast development of vaccines against the novel coronavirus disease is among the most critical steps taken to control this potentially fatal viral disease. Like other vaccines, the coronavirus disease 2019 (COVID-19) vaccines can also cause unwanted reactions. Erythema multiforme (EM) is among the oral mucocutaneous side effects of COVID-19 vaccines. This study aimed to comprehensively review the reported cases of EM since the global onset of COVID-19 vaccination. Data from 31 relevant studies regarding the type and dose of COVID-19 vaccines administered, time of initiation of symptoms, age, and gender of patients, site of involvement, patients’ medical history, and treatment options were extracted. In total, 90 patients were identified with EM as a side effect of COVID-19 vaccination across studies. EM had the highest frequency after receiving the first dose of mRNA vaccines in older individuals. The first symptoms of EM appeared in less than 3 days in 45% and after 3 days in 55% of patients. EM is not a common side effect of COVID-19 vaccination, and fear of its occurrence should not impede vaccination.

show abstract

Section: Resultsmentioning

confidence: 99%

Occurrence of erythema multiforme following COVID-19 vaccination: a review

Yousefian

Khadivi

2023

Clin Exp Vaccine Res

View full text Add to dashboard Cite

show abstract

“…In general, the etiology of EM is still not fully understood [1]. There have been several recent reports of EM or diffuse EM-like reactions following COVID-19 vaccination [10], [11], [12], [13], [14], [15], [16]. Moreover, the disease may be idiopathic, and of unknown etiology [1].…”

Section: Discussionmentioning

confidence: 99%

Serum Concentrations of Some Thelper1-Derived Cytokines in Generalized Erythema Multiforme

Tran

Phuong

Doanh

et al. 2023

Open Access Maced J Med Sci

View full text Add to dashboard Cite

BACKGROUND: Erythema multiforme (EM) is an acute mucocutaneous syndrome characterized by typical and/or atypical target lesions on the skin. The etiology is still not clear, but EM may be related to infection or medication. Clinically, there are cases of EM with atypical target lesions with generalized distribution without, or with minimal, mucosal lesions. The causes remain unknown. However, T helper cells 1 (Th1) may play an important role in EM. AIMS: The aim of the study was to investigate serum concentrations of some Th1-derived cytokines in generalized EM or generalized EM -like eruptions. METHODS: This was a sectional and descriptive study conducted at the National Hospital of Dermatology and Venereology, in Hanoi, Vietnam, from April 2017 to August 2019. There were 33 EM patients, and 32 healthy controls (HCs) participated. Serum interleukin (IL)-2, interferon-gamma (IFN-γ), and tumor necrosis factor-alpha (TNF-α) levels were measured using the fluorescence covalent microbead immunosorbent assay (ProcartaPlex Immunoassay Panels kit, Thermo Fisher Scientific, USA). The Mann–Whitney U-test was used to compare the serum IL levels of the two groups. Differences were considered to be statistically significant at p < 0.05. RESULTS: The mean age of the EM patients was 42.2 ± 17.5 years, ranging from 19 to 76 years old. Men accounted for 30.3%, women accounted for 69.7%. There were 22 patients with <1 week of onset, accounting for 66.7%; 11 patients with 1 week and those with more than 1 week accounted for 33.3%. There were 60.6% of patients using drugs before the onset. Most patients had pruritus (97%), and all had diffusely distributed skin lesions. Only 15.2% of the patients had mucosal lesions. There are 30.3% of patients with fever. The serum IFN-γ concentration of the EM group was 5.35 ± 9.88 pg/mL, higher than that of the HCs group (0.35 ± 0.77 pg/mL), the difference was statistically significant with p = 0.01 (Mann–Whitney U). The concentrations of IL-2 and TNF-α of the HCs were 24.32 ± 27.94 pg/mL and 109.74 ± 126.73 pg/mL, respectively, higher than those of the EM group (3.37 ± 5.94 pg/mL and 5.86 ± 11.88 pg/mL, respectively). The difference was statistically significant with p < 0.001. Age did not correlate with serum concentrations of cytokines in the EM group. CONCLUSION: In generalized EM, serum concentrations of IFN-γ are statistically significantly higher than those of HCs but serum concentrations of IL-2 and TNF-α were lower. There is no correlation between age and serum concentrations of cytokines in generalized erythema multiform.

show abstract

“…Cutaneous adverse reactions like hyperhidrosis, pruritis, urticaria, angioedema, post‐vaccination herpes zoster, pityriasis rosea, pityriasis rubra pilaris, erythema multiforme, erythema nodosum, generalized bullous‐fixed drug eruption, toxic epidermal necrolysis, and sweet syndrome have been reported following ChAdOx1 nCoV‐19 vaccine. 3 , 4 , 5 , 6 , 7 , 8 , 9 , 10 …”

Section: Discussionmentioning

confidence: 99%

Development of severe pemphigus vulgaris following ChAdOx1 nCoV‐19 vaccination and review of literature

Singh

Bharadwaj

et al. 2022

J of Cosmetic Dermatology

View full text Add to dashboard Cite

Vaccines are indeed a boon for tackling the present COVID‐19 pandemic. In India, ChAdOx1 nCoV‐19 (Covishield) is the most commonly used vaccine in the government vaccination program for adults more than 18 years of age. It is a recombinant vaccine developed by Oxford‐Astra Zeneca and manufactured in India by Serum Institute of India (SSI). Here, we report a case of severe pemphigus vulgaris following the second dose of ChAdOx1 nCoV‐19 vaccination in an adult male. The patient developed septicemia during the course of hospital stay, and he was managed with systemic steroids, parenteral antibiotics, and intravenous immunoglobulins (IVIg) along with proper wound care. Patient started improving within 1 month of therapy. This case is being reported in view of the rarity of pemphigus vulgaris following ChAdOx1 nCoV‐19 vaccine.

show abstract

Erythema multiforme after Covishield/ ChAdOx1 vaccination

Cited by 4 publications

References 8 publications

Occurrence of erythema multiforme following COVID-19 vaccination: a review

Occurrence of erythema multiforme following COVID-19 vaccination: a review

Serum Concentrations of Some Thelper1-Derived Cytokines in Generalized Erythema Multiforme

Development of severe pemphigus vulgaris following ChAdOx1 nCoV‐19 vaccination and review of literature

Contact Info

Product

Resources

About